Drugs / NTM-1632
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02779140 | Aug 2016 → May 2017 | botulism | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTM-1632 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02779140 ↗ |
| Modality | Monoclonal antibody | “NTM-1632 is an equimolar mixture of 3 human IgG monoclonal antibodies” PMID 33875433 ↗ Jun 2021 |
| Route | Intravenous | “single intravenous dose of NTM-1632” PMID 33875433 ↗ Jun 2021 |